Attention AACR Annual Meeting 2017 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Plenary Session 1: Cellular Immunotherapy

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
Alexander M Eggermont
Gustave Roussy Cancer Institute, Villejuif, Paris-Sud, France
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
CAR therapy for cancer: Emerging insights
Crystal L. Mackall
National Cancer Institute, Bethesda, MD, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
TIL therapy in the era of immune checkpoint blockade
John B.A.G. Haanen
Netherlands Cancer Inst., Amsterdam, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Engineering T cells with introduced TCRs to effectively target tumors
Philip D Greenberg
Fred Hutchinson Cancer Res. Ctr. & Univ. of Washington, Seattle, WA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4